TrialArthritis research & therapy2019

Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study.

Janusz Jaworski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.